Vanguard Portfolio Management
CMPX icon

Vanguard Portfolio Management’s Compass Therapeutics CMPX Stock Holding History

Vanguard Portfolio Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.26M Buy
3,771,032
+2,688,381
+248% +$7.94M ﹤0.01% 2260
2026
Q1 		$5.73M Buy
+1,082,651
New +$6.25M ﹤0.01% 2289

Other funds holding CMPX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management's CMPX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Compass Therapeutics (CMPX) stake by 248% in Q2 2026, buying an estimated $7.94M and bringing the position to 3,771,032 shares worth $8.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2260.

Vanguard Portfolio Management first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Vanguard Portfolio Management held 3,771,032 shares of Compass Therapeutics worth $8.26M as of Q2 2026.
  • Vanguard Portfolio Management bought 2,688,381 Compass Therapeutics shares in Q2 2026, an estimated $7.94M.
  • Compass Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2260 holding.
  • Vanguard Portfolio Management first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.